falsefalse

Assessing Liver Function in Patients with HCC - Episode 6

Updates in First-Line Systemic Therapy for Patients With HCC

, ,

Arndt Vogel, MD, discusses the post-hoc analyses of two key clinical trials focusing on the impact of liver function, measured by ALBI and Child-Pugh scores, on outcomes in hepatocellular carcinoma treatments.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Risk Factors of Hepatocellular Carcinoma (HCC)
    EP. 2: Importance of Assessing Liver Function in HCC
    EP. 3: Assessing Liver Function in Patients With HCC: The ALBI Score
    EP. 4: Assessing Liver Function in Patients With HCC: The Child-Pugh Score
    EP. 5: Assessing Liver Function in Patients With HCC: The MELD Score
    Now Viewing
    EP. 6: Updates in First-Line Systemic Therapy for Patients With HCC
    EP. 7: Key Outcomes Data in Patients With HCC Based on Liver Function
    EP. 8: Rivoceranib plus Camrelizumab for First-Line Treatment of HCC: Data from CARES-310
    EP. 9: The Future of Liver Function Assessments in HCC

    Related Content:

    Assessing Liver Function in Patients with HCCInsightsInsights Video Series
    Presenting the Treatment Options in EGFR-Mutant NSCLC: Weighing the Data and Incorporating the Patient Perspective
    Treatment Planning for HER2+ Breast Cancer: The Role of Ovarian Function Suppression
    Practical Recommendations for Community Oncologists
    x